Close Menu
    Facebook X (Twitter) Instagram
    ScoopSquare24
    • Home
    • News
    • AI
    • Crypto
    • Finance
    • Stocks
    Facebook X (Twitter) Instagram
    ScoopSquare24
    Home»News»Stocks»Gemini (GEMI) Stock Surges 9% Amid Reports of Interest in European Assets
    Stocks

    Gemini (GEMI) Stock Surges 9% Amid Reports of Interest in European Assets

    Oli DaleBy Oli DaleApril 10, 2026No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Key Takeaways

    • Acquirers are reportedly targeting Gemini’s closed European and U.K. units for their regulatory approvals
    • Interest centers on specific business segments rather than a complete acquisition
    • GEMI shares climbed approximately 9% following the CoinDesk story, finishing near $4.87
    • Shares have declined more than 80% from the $28 September 2025 initial public offering price
    • The company’s chief operating officer, chief financial officer, and chief legal officer all left in February

    Shares of Gemini Space Station (GEMI) climbed nearly 9% Thursday following a CoinDesk report indicating potential acquirers are evaluating portions of the Winklevoss brothers’ cryptocurrency exchange.


    GEMI Stock Card
    Gemini Space Station, Inc. Class A Common Stock, GEMI

    The stock advanced from approximately $4.48 to settle around $4.87, reaching an intraday peak of $5.18. Trading volume reached 5.5 million shares, significantly exceeding the typical 1.8 million average.

    According to the report, this isn’t about a complete takeover. CoinDesk sources indicated that interested parties are specifically targeting Gemini’s shuttered European and U.K. business units — particularly the regulatory authorizations attached to them.

    Last February, Gemini revealed plans to reduce its international headcount by 25% while ceasing operations across the U.K., European Union, and Australia. Management stated the company would concentrate exclusively on its U.S. and Singapore markets moving forward.

    Those international units possessed significant regulatory credentials. Within Europe, Gemini maintained a Markets in Crypto-Assets (MiCA) authorization, enabling service provision throughout the EU’s unified market. In Britain, it secured Financial Conduct Authority (FCA) registration as an electronic money institution.

    Obtaining such authorizations independently typically requires multiple years. This timeline creates the appeal for potential acquirers.

    Regulatory Approvals Create Acquisition Appeal

    Under MiCA regulations, cryptocurrency licenses don’t transfer automatically during acquisitions. Authorities classify such transactions as a “change of control,” requiring reassessment of the incoming owner — essentially reviewing them as new applicants. The FCA employs comparable procedures.

    While licenses aren’t simply transferable, purchasing the already-registered entity provides acquirers a substantial advantage versus starting the application process fresh.

    Gemini hasn’t issued official statements regarding the CoinDesk coverage.

    The February reorganization coincided with three senior leadership departures. COO Marshall Beard, CFO Dan Chen, and CLO Tyler Meade all exited immediately, per regulatory filings. Beard simultaneously resigned from the board. Company statements indicated his departure wasn’t connected to any operational or policy disputes.

    Significant Decline Following Public Debut

    GEMI launched its initial public offering in September 2025 priced at $28 per share. First-day trading saw it open above $37 and close around $32, representing intraday gains exceeding 30%.

    That early enthusiasm proved short-lived. Shares have subsequently plummeted over 80% from the IPO level and traded near $4.36 before Thursday’s rally.

    Short interest accounts for 15% of available shares, per FactSet information.

    The company’s current market capitalization stands at approximately $584 million. Its 52-week trading range spans from $3.91 to $45.89.

    Gemini provides services beyond standard trading platforms. Its offerings encompass institutional custody solutions, staking services, yield-generating products, payment infrastructure, and a cryptocurrency rewards credit card.

    Thursday’s advance followed the CoinDesk report’s publication. Shares concluded the session up roughly 9%, though they remain substantially below the debut price from seven months earlier.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Oli Dale
    • Website

    Related Posts

    Replimune (REPL) Shares Plunge Nearly 20% Following Second FDA Rejection of RP1 Melanoma Treatment

    April 10, 2026

    Replimune (REPL) Shares Plunge Nearly 20% Following Second FDA Rejection of RP1 Melanoma Treatment

    April 10, 2026

    Michael Burry’s Latest Portfolio Moves: Chinese Stocks In, Tech Giants Out

    April 10, 2026
    Leave A Reply Cancel Reply

    Breaking News
    Parameter

    Angel Studios (ANGX) Stock: Slides 22% After $30M Share Offering Announcement

    Parameter
    Apr 10, 2026 6:27 PM
    Blockonomi

    Flare Proposes FLR Overhaul with MEV Capture and Inflation Cut

    Blockonomi
    Apr 10, 2026 6:19 PM
    Parameter

    Michael Burry Expands Chinese Tech Holdings While Doubling Down on Nvidia (NVDA) and Palantir (PLTR) Short Positions

    Parameter
    Apr 10, 2026 6:04 PM
    Blockonomi

    Fair Isaac (FICO) Stock Plunges 13% Amid Senate Probe and AI Headwinds

    Blockonomi
    Apr 10, 2026 6:03 PM
    Parameter

    Linkers Industries Limited (LNKS) Stock: Jumps on $16M Raise and Cashless Warrant Conversion

    Parameter
    Apr 10, 2026 6:02 PM
    Blockonomi

    Fair Isaac (FICO) Stock Plunges 13% Amid Senate Probe and AI Competitive Fears

    Blockonomi
    Apr 10, 2026 6:02 PM
    Blockonomi

    Replimune (REPL) Shares Plunge 19% Following Second FDA Rejection of RP1 Melanoma Treatment

    Blockonomi
    Apr 10, 2026 6:02 PM
    Blockonomi

    Replimune (REPL) Stock Plunges 19% Following Second FDA Rejection of Melanoma Treatment

    Blockonomi
    Apr 10, 2026 6:02 PM
    Moneycheck

    Replimune (REPL) Shares Plunge Nearly 20% Following Second FDA Rejection of RP1 Melanoma Treatment

    Moneycheck
    Apr 10, 2026 6:02 PM
    Blockonomi

    Replimune (REPL) Shares Plunge 19% as FDA Issues Second Rejection for Melanoma Treatment

    Blockonomi
    Apr 10, 2026 6:02 PM
    Moneycheck

    Replimune (REPL) Shares Plunge Nearly 20% Following Second FDA Rejection of Melanoma Treatment

    Moneycheck
    Apr 10, 2026 6:02 PM
    Blockonomi

    Michael Burry Reveals New Positions in Chinese Stocks While Doubling Down Against Nvidia (NVDA) and Palantir (PLTR)

    Blockonomi
    Apr 10, 2026 6:02 PM
    Blockonomi

    Michael Burry’s Latest Portfolio Moves: Long on Chinese Tech, Short on Nvidia (NVDA) and Palantir (PLTR)

    Blockonomi
    Apr 10, 2026 6:01 PM
    Moneycheck

    Michael Burry Expands Chinese Tech Holdings While Doubling Down on Nvidia (NVDA) and Palantir (PLTR) Short Positions

    Moneycheck
    Apr 10, 2026 6:01 PM
    Blockonomi

    Michael Burry Targets Chinese Tech Giants While Doubling Down on Nvidia (NVDA) and Palantir (PLTR) Shorts

    Blockonomi
    Apr 10, 2026 6:01 PM
    Facebook X (Twitter) Instagram Pinterest
    ScoopSquare24

    Copyright © 2013 - 2026 Kooc Media Ltd. All rights reserved. Registered Company No.05695741
    Our Sites: FlowPresets / GardenBeast / GolfMonster / Blockonomi / Money Check / CoinCentral / Parameter / Circlo / Computing.net

    Type above and press Enter to search. Press Esc to cancel.